Das Mikrobiom als Therapieziel bei funktionellen und chronisch entzündlichen Magen-Darm-Erkrankungen

Zusammenfassung

Das Mikrobiom spielt eine wichtige Rolle im Krankheitsgeschehen funktioneller sowie chronisch entzündlicher Darmerkrankungen (CED). Im Zuge der gesteigerten Aufmerksamkeit für das Mikrobiom wurde nach der Etablierung der Probiotikatherapie in den S3-Leitlinien für Colitis ulcerosa und das Reizdarmsyndrom auch die Therapieform des fäkalen Mikrobiotatransfers wiederentdeckt. Die standardisierte Anwendung im klinischen Alltag für die Indikationen CED und Reizdarmsyndrom ist jedoch noch nicht in Aussicht. Weitere Ansätze mit potenziell positiven Effekten auf das Mikrobiom bieten darüber hinaus Phytotherapeutika. Bei Patienten, die an funktionellen oder chronisch entzündlichen Darmbeschwerden leiden, können diese das Behandlungsspektrum wirkungsvoll ergänzen und erweitern.

Abstract

The microbiome plays an important role in the disease process of functional as well as chronic inflammatory bowel diseases. As a result of the increased attention paid to the microbiome, the therapy of the fecal microbiota transfer has been rediscovered after the establishment of the probiotics therapy in the S3-guidelines for ulcerative colitis and irritable bowel syndrome. However, there is still no prospect for a standardized application in daily clinical practice for the indications CID and irritable bowel syndrome. In addition, phytotherapeutic agents offer further approaches with potentially positive effects on the microbiome. They can effectively complement and expand the treatment spectrum in patients suffering from functional or chronic inflammatory intestinal complaints.

Schlüsselwörter

Mikrobiom - CED - Fäkaler Mikrobiota-Transfer - Probiotika - Phytotherapie

Key words

Microbiome - CID - fecal microbiota transfer - probiotics - phytotherapy

• Literatur

• 1 Hoffmann JC, Zeitz M. S3 guideline by the German Society of Digestive and Metabolic Diseases and the Competence Network of Chronic Inflammatory Bowel diseases on diagnosis and therapy of ulcerative colitis. An update. Med Klin 2005; 100 (01) 43-50
• 2 Layer P, Andresen V, Pehl C. et al. Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management. Z Gastroenterol 2011; 49 (02) 237-293
• 3 Preiss JC, Bokemeyer B, Buhr HJ. et al. Updated German clinical practice guideline on „Diagnosis and treatment of Crohn’s disease“ 2014. Z Gastroenterol 2014; 52 (12) 1431-1484
• 4 Li SS, Zhu A, Benes V. et al. Durable coexistence of donor and recipient strains after fecal microbiota transplantation. Science 2016; 352 (6285) 586-589
• 5 Moayyedi P, Surette MG, Kim PT. et al. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology 2015; 149 (01) 102-109.e6
• 6 Paramsothy S, Kamm MA, Kaakoush NO. et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 2017; 389 (10075) 1218-1228
• 7 Rossen NG, Fuentes S, van der Spek MJ. et al. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. Gastroenterology 2015; 149 (01) 110-118.e114
• 8 Rossen NG, MacDonald JK, de Vries EM. et al. Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review. World J Gastroenterol 2015; 21 (17) 5359-5371
• 9 Shi Y, Dong Y, Huang W. et al. Fecal Microbiota Transplantation for Ulcerative Colitis: A Systematic Review and Meta-Analysis. PloS one 2016; 11 (06) e0157259
• 10 Sun D, Li W, Li S. et al. Fecal Microbiota Transplantation as a Novel Therapy for Ulcerative Colitis: A Systematic Review and Meta-Analysis. Medicine 2016; 95 (23) e3765
• 11 Holtmann G, Talley NJ. Herbal medicines for the treatment of functional and inflammatorybowel disorders. Clin Gastroenterol Hepatol 2015; 13 (03) 422-432
• 12 Langhorst J, Koch AK. Distinct patterns of short chain fatty acids in patients with ulcerative colitis experiencing a flare during treatment with mesalamine or a herbal combination of myrrh, chamomile flowers and coffee charcoal. Gastroenterol 2017; 47 (05) (Suppl. 01) 616
• 13 Langhorst J, Frede A, Knott M. et al. Distinct kinetics in the frequency of peripheral CD4+ T cells in patients with ulcerative colitis experiencing a flare during treatment with mesalazine or with a herbal preparation of myrrh, chamomile, and coffee charcoal. PloS one 2014; 9 (08) e104257
• 14 Chapman MA, Grahn MF, Boyle MA. et al. Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis. Gut 1994; 35 (01) 73-76
• 15 Wong JM, de Souza R, Kendall CW. et al. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol 2006; 40 (03) 235-243
• 16 Machiels K, Joossens M, Sabino J. et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 2014; 63 (08) 1275-1283
• 17 Langhorst J, Varnhagen I, Schneider SB. et al. Randomised clinical trial: a herbal preparation of myrrh, chamomile and coffee charcoal compared with mesalazine in maintaining remission in ulcerative colitis--a double-blind, double-dummy study. Aliment Pharmacol Ther 2013; 38 (05) 490-500
• 18 Hanai H, Iida T, Takeuchi K. et al. Curcumin Maintenance Therapy for Ulcerative Colitis: Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. Clin Gastroenterol Hepatol 2006; 4 (12) 1502-1506
• 19 Lang A, Salomon N, Wu JCY. et al. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mildto-Moderate Ulcerative Colitis in a Randomized Controlled Trial. Clin Gastroenterol Hepatol 2015; 13 (08) 1444-1449 e1441
• 20 Singla V, Pratap Mouli V, Garg SK. et al. Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis – a randomized, placebo-controlled, pilot study. J Crohns Colitis 2014; 8 (03) 208-214
• 21 Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL. et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn’s Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol 1999; 94 (02) 427-433
• 22 Biedermann L, Mwinyi J, Scharl M. et al. Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis – an open pilot study. J Crohns Colitis 2013; 7 (04) 271-279
• 23 Krebs S, Omer TN, Omer B. Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn’s disease – A controlled clinical trial. Phytomedicine 2010; 17 (05) 305-309
• 24 Omer B, Krebs S, Omer H. et al. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn’s disease: A double-blind placebo-controlled study. Phytomedicine 2007; 14 (02) 3 87-95
• 25 Gupta I, Parihar A, Malhotra P. et al. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta medica 2001; 67 (05) 391-395
• 26 Gupta I, Parihar A, Malhotra P. et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Europ J Med Res 1997; 2 (01) 37-43
• 27 Gerhardt H, Seifert F, Buvari P. et al. Therapy of active Crohn disease with Boswellia serrata extract H 15. Z Gastroenterol 2001; 39 (01) 11-17
• 28 Holtmeier W, Zeuzem S, Preiss J. et al. Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn’s disease: good safety profile but lack of efficacy. Inflamm Bow Dis. 2011; 17 (02) 573-582
• 29 Sandborn WJ, Targan SR, Byers VS. et al. Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol 2013; 108 (01) 90-98
• 30 Tang T, Targan SR, Li ZS. et al. Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis – a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther 2011; 33 (02) 194-202
• 31 Ben-Arye E, Goldin E, Wengrower D. et al. Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial. Scand J Gastroenterol 2002; 37 (04) 444-449
• 32 Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol 2014; 48 (06) 505-512
• 33 Lauche R, Janzen A, Ludtke R. et al. Efficacy of Caraway Oil Poultices in Treating Irritable Bowel Syndrome – A Randomized Controlled Cross-Over Trial. Digestion 2015; 92 (01) 22-31
• 34 Madisch A, Holtmann G, Plein K. et al. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 2004; 19 (03) 271-279